Chapter 37. Chronic Myeloid Leukemia

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8 and
  5. Richard Lottenberg MD, FACP Professor9
  1. Irwin Walker MBBS, FRACP, FRCPC

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch37

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Walker, I. (2008) Chronic Myeloid Leukemia, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch37

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. Hematology and Bone Marrow Transplantation, McMaster University Medical Centre, Hamilton, Ontario, Canada

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857



  • Chronic myeloid leukemia (CML);
  • recommended treatment for patients with CML;
  • International Randomized Interferon versus STI571 (IRIS) trial;
  • bone marrow transplantation;
  • imatinib (IRIS trial) having long-term event-free survival (EFS);
  • failed imatinib therapy and other options;
  • Nilotinib (AMN107, Novartis) - aminopyrimidine-derivative tyrosine kinase inhibitor


This chapter contains sections titled:

  • Introduction

  • Questions

  • Literature-search strategy and inclusions

  • What is the recommended treatment for patients with CML at the time of diagnosis?

  • What is the place of bone marrow transplantation at the time of diagnosis?

  • What is the recommended treatment for patients with CML where first line treatment has failed?

  • References